Pharmacokinetics of unboosted atazanavir in treatment-experienced HIV-infected children, adolescents and young adults

Tim R. Cressey; Rohan Hazra; Andrew Wiznia; Marc Foca; Patrick Jean-Philippe; Bobbie Graham; Jennifer R. King; Paula Britto; Vincent J. Carey; Edward P. Acosta; Ram Yogev

doi:10.1097/INF.0000000000001320

Pharmacokinetics of unboosted atazanavir in treatment-experienced HIV-infected children, adolescents and young adults

Tim R. Cressey
, Rohan Hazra
, Andrew Wiznia
, Marc Foca
, Patrick Jean-Philippe
, Bobbie Graham
, Jennifer R. King
, Paula Britto
, Vincent J. Carey
, Edward P. Acosta
, Ram Yogev

Research output: Contribution to journal › Article › peer-review

2 Scopus citations

Abstract

HIV protease inhibitor use in pediatrics is challenging due to the poor palatability and/or toxicity of concomitant low-dose ritonavir. Atazanavir without ritonavir (unboosted) is not recommended for patients with prior virologic failure, a common problem for perinatally-infected adolescents. Atazanavir 400 mg once-daily provided suboptimal exposure. Higher unboosted doses or splitting the daily dose to twice-daily warrants investigation in this treatment-experienced population.

Original language	English (US)
Pages (from-to)	1333-1335
Number of pages	3
Journal	Pediatric Infectious Disease Journal
Volume	35
Issue number	12
DOIs	https://doi.org/10.1097/INF.0000000000001320
State	Published - Nov 28 2016
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Antiretrovirals
Atazanavir
Pediatrics
Pharmacokinetics

ASJC Scopus subject areas

Pediatrics, Perinatology, and Child Health
Microbiology (medical)
Infectious Diseases

Access to Document

10.1097/INF.0000000000001320

Cite this

Cressey, T. R., Hazra, R., Wiznia, A., Foca, M., Jean-Philippe, P., Graham, B., King, J. R., Britto, P., Carey, V. J., Acosta, E. P., & Yogev, R. (2016). Pharmacokinetics of unboosted atazanavir in treatment-experienced HIV-infected children, adolescents and young adults. Pediatric Infectious Disease Journal, 35(12), 1333-1335. https://doi.org/10.1097/INF.0000000000001320

@article{4c2dc1ae6f0440ce83026a0475e84b29,

title = "Pharmacokinetics of unboosted atazanavir in treatment-experienced HIV-infected children, adolescents and young adults",

abstract = "HIV protease inhibitor use in pediatrics is challenging due to the poor palatability and/or toxicity of concomitant low-dose ritonavir. Atazanavir without ritonavir (unboosted) is not recommended for patients with prior virologic failure, a common problem for perinatally-infected adolescents. Atazanavir 400 mg once-daily provided suboptimal exposure. Higher unboosted doses or splitting the daily dose to twice-daily warrants investigation in this treatment-experienced population.",

keywords = "Antiretrovirals, Atazanavir, Pediatrics, Pharmacokinetics",

author = "Cressey, \{Tim R.\} and Rohan Hazra and Andrew Wiznia and Marc Foca and Patrick Jean-Philippe and Bobbie Graham and King, \{Jennifer R.\} and Paula Britto and Carey, \{Vincent J.\} and Acosta, \{Edward P.\} and Ram Yogev",

year = "2016",

month = nov,

day = "28",

doi = "10.1097/INF.0000000000001320",

language = "English (US)",

volume = "35",

pages = "1333--1335",

journal = "Pediatric Infectious Disease Journal",

issn = "0891-3668",

publisher = "Lippincott Williams and Wilkins",

number = "12",

}

TY - JOUR

T1 - Pharmacokinetics of unboosted atazanavir in treatment-experienced HIV-infected children, adolescents and young adults

AU - Cressey, Tim R.

AU - Hazra, Rohan

AU - Wiznia, Andrew

AU - Foca, Marc

AU - Jean-Philippe, Patrick

AU - Graham, Bobbie

AU - King, Jennifer R.

AU - Britto, Paula

AU - Carey, Vincent J.

AU - Acosta, Edward P.

AU - Yogev, Ram

PY - 2016/11/28

Y1 - 2016/11/28

N2 - HIV protease inhibitor use in pediatrics is challenging due to the poor palatability and/or toxicity of concomitant low-dose ritonavir. Atazanavir without ritonavir (unboosted) is not recommended for patients with prior virologic failure, a common problem for perinatally-infected adolescents. Atazanavir 400 mg once-daily provided suboptimal exposure. Higher unboosted doses or splitting the daily dose to twice-daily warrants investigation in this treatment-experienced population.

AB - HIV protease inhibitor use in pediatrics is challenging due to the poor palatability and/or toxicity of concomitant low-dose ritonavir. Atazanavir without ritonavir (unboosted) is not recommended for patients with prior virologic failure, a common problem for perinatally-infected adolescents. Atazanavir 400 mg once-daily provided suboptimal exposure. Higher unboosted doses or splitting the daily dose to twice-daily warrants investigation in this treatment-experienced population.

KW - Antiretrovirals

KW - Atazanavir

KW - Pediatrics

KW - Pharmacokinetics

UR - https://www.scopus.com/pages/publications/84984700603

UR - https://www.scopus.com/pages/publications/84984700603#tab=citedBy

U2 - 10.1097/INF.0000000000001320

DO - 10.1097/INF.0000000000001320

M3 - Article

C2 - 27583590

AN - SCOPUS:84984700603

SN - 0891-3668

VL - 35

SP - 1333

EP - 1335

JO - Pediatric Infectious Disease Journal

JF - Pediatric Infectious Disease Journal

IS - 12

ER -

Pharmacokinetics of unboosted atazanavir in treatment-experienced HIV-infected children, adolescents and young adults

Abstract

UN SDGs

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this